Remove 2016 Remove Immunization Remove Vaccines
article thumbnail

Indian Immunologicals gets regulatory approval for measles-rubella (MR) vaccine

Express Pharma

Indian Immunologicals announced receipt of approval from Drugs Controller General of India and State Drug Control Administration for manufacturing of Measles-Rubella (MR) Vaccine. Under an exclusive agreement, Polyvac, Vietnam will supply the Measles vaccine component to IIL.

article thumbnail

Merck and Moderna partner to develop and sell cancer vaccine

Pharmaceutical Technology

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs.

Vaccines 115
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

mRNA non-vaccine therapeutics to generate $2 billion by 2028

European Pharmaceutical Review

According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. The post mRNA non-vaccine therapeutics to generate $2 billion by 2028 appeared first on European Pharmaceutical Review.

article thumbnail

BREAKING NEWS: Moderna sues Pfizer and BioNTech over mRNA COVID-19 vaccines

European Pharmaceutical Review

Moderna has filed patent infringement lawsuits alleging that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty ® infringes patents Moderna filed between 2010 and 2016 covering its foundational messenger RNA (mRNA) technology. ” But why sue now? .” ” But why sue now?

article thumbnail

Towards ‘smart’ vaccine development and manufacturing

European Pharmaceutical Review

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Novel biotechnology platforms for vaccine development.

article thumbnail

HIV vaccines suffer setbacks but new approaches could turn the tide

Pharmaceutical Technology

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccines 117
article thumbnail

BioNTech’s RNA vaccine sparks potential in pancreatic cancer

Pharmaceutical Technology

Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.

Vaccines 138